CA2828595C - Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque - Google Patents

Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque Download PDF

Info

Publication number
CA2828595C
CA2828595C CA2828595A CA2828595A CA2828595C CA 2828595 C CA2828595 C CA 2828595C CA 2828595 A CA2828595 A CA 2828595A CA 2828595 A CA2828595 A CA 2828595A CA 2828595 C CA2828595 C CA 2828595C
Authority
CA
Canada
Prior art keywords
copper
patient
diabetic
diabetes
trientine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2828595A
Other languages
English (en)
Other versions
CA2828595A1 (fr
Inventor
Garth James Smith Cooper
John Richard Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHILERA NEW ZEALAND Ltd
Original Assignee
PHILERA NEW ZEALAND Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHILERA NEW ZEALAND Ltd filed Critical PHILERA NEW ZEALAND Ltd
Priority to CA2982327A priority Critical patent/CA2982327A1/fr
Priority claimed from CA2478997A external-priority patent/CA2478997C/fr
Publication of CA2828595A1 publication Critical patent/CA2828595A1/fr
Application granted granted Critical
Publication of CA2828595C publication Critical patent/CA2828595C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Une méthode damélioration de la réparation de tissu endommagé de tissu chez un patient mammalien à partir de celui du myocarde, de larbre vasculaire et des organes qui dépendent de larbre vasculaire, ladite méthode comprenant ou intégrant létape de donner au patient, ou dadministrer au patient, un agent ou des agents efficaces pour réduire les valeurs de cuivre du corps du patient à une teneur suffisante pour améliorer la réparation des tissus.
CA2828595A 2002-03-08 2003-03-10 Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque Expired - Fee Related CA2828595C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2982327A CA2982327A1 (fr) 2002-03-08 2003-03-10 Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
NZ517721 2002-03-08
NZ51772102 2002-03-08
NZ51772502 2002-03-11
NZ517725 2002-03-11
US36438202P 2002-03-12 2002-03-12
US60/364,382 2002-03-12
CA2478997A CA2478997C (fr) 2002-03-08 2003-03-10 Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2478997A Division CA2478997C (fr) 2002-03-08 2003-03-10 Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2982327A Division CA2982327A1 (fr) 2002-03-08 2003-03-10 Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque

Publications (2)

Publication Number Publication Date
CA2828595A1 CA2828595A1 (fr) 2003-09-25
CA2828595C true CA2828595C (fr) 2017-11-28

Family

ID=46801737

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2828595A Expired - Fee Related CA2828595C (fr) 2002-03-08 2003-03-10 Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque
CA2982327A Abandoned CA2982327A1 (fr) 2002-03-08 2003-03-10 Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2982327A Abandoned CA2982327A1 (fr) 2002-03-08 2003-03-10 Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque

Country Status (3)

Country Link
CA (2) CA2828595C (fr)
ES (1) ES2642633T3 (fr)
PT (2) PT1487431E (fr)

Also Published As

Publication number Publication date
CA2982327A1 (fr) 2003-09-25
ES2642633T3 (es) 2017-11-17
CA2828595A1 (fr) 2003-09-25
PT1487431E (pt) 2012-08-02
PT2500018T (pt) 2017-10-04

Similar Documents

Publication Publication Date Title
CA2478997C (fr) Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque
JP2005533003A5 (fr)
WO2004017957A1 (fr) Prevention et/ou traitement de maladies cardio-vasculaires et/ou insuffisance cardiaque associee
WO2003075910A1 (fr) Prevention et/ou traitement d'une maladie vasculaire, d'une cardiomyopathie et/ou d'une defaillance cardiaque associee
Huebschmann et al. Diabetes and advanced glycoxidation end products
Hoffman et al. Myocardial reperfusion injury: etiology, mechanisms, and therapies
Tan et al. AGE, RAGE, and ROS in diabetic nephropathy
Folli et al. The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro-and macrovascular complications: avenues for a mechanistic-based therapeutic approach
Son Reactive oxygen and nitrogen species in pathogenesis of vascular complications of diabetes
Monnier Intervention against the Maillard reaction in vivo
Kishi et al. Oxidative stress and the role of redox signalling in chronic kidney disease
Adler et al. Impaired regulation of renal oxygen consumption in spontaneously hypertensive rats
US7652037B2 (en) Methods of lowering lipid levels in a mammal
US20030060490A1 (en) Method for the treatment and prevention of urinary stone disease
Tsutsui et al. Oxidative stress in cardiac and skeletal muscle dysfunction associated with diabetes mellitus
Yan et al. Iron accumulation and lipid peroxidation: implication of ferroptosis in diabetic cardiomyopathy
CA2828595C (fr) Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque
NZ545724A (en) Use of a copper chelator for preventing and/or treating cardiovascular disease and/or associated heart failure
Antonopoulos et al. Novel therapeutic strategies targeting vascular redox in human atherosclerosis
US8580854B2 (en) Methods of suppression of rage gene expression and rage triggered inflammatory genes by selected age-inhibitors
Alvarez et al. Impact of advanced glycation end products on endothelial function and their potential link to atherosclerosis
Schalkwijk Therapeutic interventions in the glyc (oxid) ation pathway
Lima et al. Research Article Curcumin, Alone or in Combination with Aminoguanidine, Increases Antioxidant Defenses and Glycation Product Detoxification in Streptozotocin-Diabetic Rats: A Therapeutic Strategy to Mitigate Glycoxidative Stress
Coughlan et al. Can you reduce your AGE?: Strategies to prevent AGE accumulation in diabetes
Liao et al. New Approach to Preventing and Treating Diabetes Mellitus: Focus on Advanced Glycation End Products (AGE)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131001

MKLA Lapsed

Effective date: 20210310